The development of broad-spectrum metallo-b-lactamase (MBL) inhibitors is challenging due to structural diversity and differences in metal utilisation by these enzymes. Analysis of structural data, followed by non-denturing mass spectrometric analyses, identified thiols proposed to inhibit representative MBLs from all three sub-classes: B1, B2 and B3. Solution analyses led to the identification of broad spectrum inhibitors, including potent inhibitors of the CphA MBL (Aeromonas hydrophila). Structural studies revealed that, as observed for other B1 and B3 MBLs, inhibition of the L1 MBL thiols involves metal chelation. Evidence is reported that this is not the case for inhibition of the CphA enzyme by some thiols; the crystal structure of the CphA-Zn-inhibitor complex reveals a binding mode in which the thiol does not interact with the zinc. The structural data enabled the design and the production of further more potent inhibitors. Overall the results suggest that the development of reasonably broad-spectrum MBL inhibitors should be possible.
Introduction
b-Lactamases (BLs) are classified into those employing a nucleophilic serinyl residue (classes A, C and D) and those binding one or two zinc ions (metallo-b-lactamases, MBLs, class B) at their active site. Medicinal attention has primarily focused on the serine BLs, and inhibitors of these enzymes are widely used. However, MBLs hydrolyze most b-lactam antibiotics and are an increasing clinical problem (for a review see ref. 1) . MBLs can be divided into three subclasses on the basis of their substrate selectivity. Sub-classes B1 and B3 display a broad substrate selectivity whereas sub-class B2 most efficiently hydrolyze carbapenems.
2,3 B1 MBLs, including BcII (Bacillus cereus) and IMP-1 (Pseudomonas aeruginosa), can employ either one or two active site Zn(II) ions, whereas B3 MBLs, e.g. FEZ-1 (Legionella gormanii) and L1 (Stenotrophomonas maltophilia), are only active with two Zn(II) ions. The B2 MBL CphA (Aeromonas hydrophilia) is active as a mono-zinc protein but is non-competitively inhibited by the presence of a second Zn(II). 4 Crystal and solution structures of representatives from the three subclasses reveal significant structural differences in the active site pocket 5-7 and in a loop involved in substrate binding.
8,9
The active site metal-binding chemistry and structural variations make the development of broad-spectrum MBL inhibitors challenging. At present, there are no reports of individual MBL inhibitors with sub-micromolar K i values against all three MBL sub-classes; however, such a property will be highly desirable, if not a prerequisite, for a clinically useful compound. Thiols are the most studied MBL inhibitors, with various derivatives having been described (e.g. thiomandelic acid, 10 D-captopril, 11 6-(mercaptomethyl)penicillinates, 12 homocysteinylcontaining peptides 13 and derivatives of mercaptobenzoic acid).
14 (±)-Thiomandelic acid (1) and D-captopril (2) are reported to be potent inhibitors of sub-classes B1 and B3. However, 1 and 2 fail to potently inhibit members of the B2 sub-class (K i = 144 lM for 1, and 72 lM for 2), and thus are probably not useful broad-spectrum inhibitors.
Here we report how the application of MS-based screening coupled to structural analyses led to the identification of broadspectrum inhibitors of clinically relevant metallo-b-lactamases.
Initial screening and assays
With the aim of identifying molecules capable of inhibiting MBLs from all three sub-classes, we analysed X-ray structures for representative MBLs from the three sub-classes: BcII (B1), IMP-1 (B1), CphA (B2), L1 (B3) and FEZ-1 (B3) (Fig. 1) .
Based on the structural analyses, selected thiols were then synthesised (Scheme 1) and screened for binding to representative MBLs (BcII, CphA and FEZ-1) using electrospray ionisation-MS Fig. 1 Superimposition of views derived from the crystal structures of BcII (sub-class B1, orange, PDB code 1BVT), 15 IMP-1 (sub-class B1, yellow, PDB code 1DDK), 8 CphA (sub-class B2, blue, PDB code 18XI), 5 L1 (sub-class B3, pink, PDB code 1SML) 16 and FEZ-1 (sub-class B3, grey, PDB code 1K07). 17 (a) Overall folds and (b) close-up of selected residues at the active sites (nitrogen in blue, oxygen in red and sulfur in orange). The figure highlights the overall structural similarities between these MBLs, including between the dizinc-binding enzymes (BcII, IMP-1, L1 and FEZ-1) and the monozinc-binding MBLs (e.g. CphA, in blue). The numbering scheme is that for the BcII enzyme. under non-denaturing ionisation conditions (Fig. 2) . Although there are limitations to the use of MS for screening for enzyme inhibitors, 18-21 ESI-MS has been productively used to analyse the binding of inhibitors to MBLs including in dynamic thiol exchange methodology.
14
Compound 3 was prepared in three steps as reported (16% overall yield) 22 (Scheme 1a). a-Mercaptoketone 4 was prepared from commercially available a-bromoketone (65% overall yield; all yields unoptimised) (Scheme 1b). a-Bromoketone 16 was alkylated using potassium thioacetate to give 17, then hydrolysed to give 4. 5a,b and 8a-c were prepared, using an alternative to the reported methods, 22,23 in three steps from the corresponding amino acids (overall yields: 12 to 48%) (Scheme 1c). Thus 3-bromopropionyl chloride was treated with the methyl ester of suitable amino acid hydrochlorides to give bromides 18-22. Substitution using potassium thioacetate gave acetylthiolates 23-27; subsequent hydrolysis of the protecting groups led to the formation of mercaptocarboxylates 5a,b and 8a-c in moderate Fig. 2 Deconvoluted ESI-MS spectra under non-denaturing conditions showing a) BcII-Zn 2 , b) BcII-Zn 2 + 3 (1 eq.), c) BcII-Zn 2 + 4 (1 eq.), d) BcII-Zn 2 + 5a (1 eq.), e) CphA-Zn, f) CphA-Zn + 3 (1 eq.), g) CphA-Zn + 4 (1 eq.), h) CphA-Zn + 5a (1 eq.), i) FEZ-1-Zn 2 , j) FEZ-1-Zn 2 + 3 (1 eq.), k) FEZ-1-Zn 2 + 4 (1 eq.) and l) FEZ-1-Zn 2 + 5a (1 eq.). * FEZ-1-Zn 2 + methionine (N-terminal ± methionine residue was confirmed by tryptic digestion followed by MALDI-MS analyses). yields. D-Phenylglycine derivative 8a was obtained as a racemic mixture in the last deprotection step. Compound 9 was prepared in two steps from D-phenylalanine methyl ester hydrochloride (22% overall yield) (Scheme 1d). Protection of commercially available alcohol 29 using tert-butyldiphenylsilyl chloride (TBDPSCl) and imidazole to give 30, followed by methyl ester hydrolysis (LiOH) gave 31 in good yield. Carboxylic acid 31 was converted into the corresponding acyl chloride (oxalyl chloride), which was then reacted with D-proline to give carboxylic acid 32 in good overall yield. Deprotection of the silyl group using fluoridric acid in pyridine afforded the desired hydroxycarboxylic acid in reasonable yield. 10 was prepared in one step from D-proline (Scheme 1e). 11 was prepared in two steps from D-phenylalanine methyl ester hydrochloride (11% overall yield) (Scheme 1g). 12 was prepared in one step from D-phenylalanine in 41% yield under SchottenBaumann conditions (Scheme 1f).
24
With the exceptions of 5a and 5b, which were not observed to bind significantly to CphA and FEZ-1 by ESI-MS under the applied experimental conditions, two of the tested compounds (3 and 4, Fig. 3 ) showed a significant ability to form enzymemetal-ligand complexes with all the tested MBLs; CphA-Zn-5a or 5b and FEZ-1-Zn 2 -5a or 5b complexes were observed when an excess of 5a,b was used (data not shown). Thiols 5a,b are less functionalised derivatives of the reported MBL inhibitors 6 and 7 (see below).
8, 25 Thiols 3 and 4 formed significant CphA-Znligand complexes (Fig. 2d,e) , but did not induce the binding of a second zinc ion in the active site of CphA as reported for 1. carboxylate groups of inhibitors not only influences the potency of MBL inhibition by mercaptocarboxylate, as proposed, 10 but can also influence the mechanism of inhibition via modification of the MBL-metal-ligand stoichiometry, i.e. 1 binds as a CphA-Zn 2 -ligand complex but 3 and 4 bind as CphA-Zn-ligand complexes (at least by MS analyses). Compounds 3-5 were then screened for inhibition against MBLs from all three sub-classes (Table 1 ). Strikingly, 3 and 4 were found to inhibit all the tested MBLs. 3 is the first reported broad spectrum MBL inhibitor with K i values <1 lM for all MBLs. 3 (K i = 90 nM) and 4 (K i = 50 nM) were the most potent reported inhibitors for the monozinc CphA MBL ( Table 1) .
The results also imply that mercaptocarboxylate compounds that bind as CphA-Zn complexes rather than CphA-Zn 2 complexes are more potent CphA inhibitors; thus, thiol 4, which appears to bind as a monozinc complex to CphA (by ESI-MS), is ca. 3000 times more potent than 1, which binds to the CphA MBL preferentially as a dizinc complex.
14 Compounds 5a and 5b were found to significantly inhibit sub-classes B1 and B3 (Fig. 3 ).
8

Modelling and NMR studies
To investigate the broad-spectrum nature of the inhibition of 4, docking studies were carried out with representatives of each sub-class (IMP-1, CphA and L1). Initially, to test the utility of the modelling technique, 7 was docked into IMP-1-Zn-7
8
(with 7 extracted) using different zinc coordination geometries (data not shown). A close correlation between the structure of the IMP-1-Zn-7 complex in the reported X-ray structure 8 and the highest scoring docked conformation was obtained using a tetrahedral geometry for both active site zinc cations. A trigonal bipyramidal geometry was used for the monozinc CphA based on the previously reported crystallographic data for the complexed CphA structure. 5 In all cases, the choice of the metal coordination type of the enzyme as well as the parametrisation of the ligand (i.e. ionisation state of the thiol/carboxylate groups and the tautomeric form of the amide bond) were found to be important for good correlation between the binding mode observed in the crystal structures and the modelling data. Generally, for dizinc MBLs, the lowest rms deviations between the MBL-Zn 2 -ligand crystal structures and the highest scoring modelled structures were obtained when using deprotonated SH/CO 2 H groups and the amide tautomer form of the inhibitor. Conversely, the use of deprotonated SH/CO 2 H and the imidic acid tautomer form achieved the most consistent results (and the highest docking scores) for the monozinc CphA. These observations highlight the influence of the preparation of molecules for docking studies with metalloenzymes.
Compound 4 was predicted to interact with the dizinc MBLs (IMP-1 and L1) via a metal bridging chelation involving its thiolate and a hydrogen-bond between its carbonyl group and the conserved MBL hydrogen-bond donor region (Fig. 1, Fig. 4a ,c). The proposed bridging metal chelation of 4 is precedented by various crystallographic and solution studies on dizinc MBLs.
7,8,11,17
In contrast, the modelling studies led to the prediction that both the thiolate and carbonyl groups of 4 chelate the monozinc ion CphA (Fig. 4b) , indicating a potential for the same inhibitor to adopt different (predominant) binding modes to different MBLs. Docking of 3 resulted in a more complex analysis due to several possible predicted structures for the MBL-3 complexes (data not shown). However, the results suggested that the key enzyme-inhibitor interactions involve the carboxylate group of 3 with the conserved hydrogen-bond region ( Fig. 1 ) and its thiolate group with the two zinc ions. 5a was predicted to bind similarly to the dizinc MBLs with similar interactions predicted for 3 and 4, i.e. the C-7 carboxylate of 5a interacting with the MBL hydrogenbond donor region and the thiolate with the zinc ions ( Fig. 4d and Fig. 5f ). In contrast, when 5a was docked into the monozinc MBL CphA the results suggested that 5a may chelate to the zinc cation via its C-7 carboxylate and imidic acid nitrogen (Fig. 4e) . In this mode the C-4 carbonyl of 5a can interact with the side chains of Asp120 and His118 and the thiolate group is positioned to make hydrogen bonds with the hydroxyl side chains of Thr119 and Thr157, i.e. not to the zinc ions. Although not precedented by any structural work on thiol MBL inhibitors, this binding mode is consistent with the reported mode of zinc chelation in the complex between hydrolysed biapenem and CphA.
5
These modelling studies suggested that the inhibition of CphA may be enhanced by hydrophobic interactions with residues such as Val67, possibly explaining the lack of significant inhibition of 5a,b (at 100 lM) vs. CphA. Significantly they also suggest that mercaptocarboxylates do not always inhibit monozinc MBLs via a thiol-zinc interaction.
To obtain structural information on the binding of 5a,b to the sub-class B1 MBL and to test the modelling studies, NMR studies of BcII-Zn 2 with 5a and 5b were then carried out. The imidazole resonances of the metal binding histidine residues (His86, His88, His149 and His210) 6 are useful probes of the effects of inhibitors. In the absence of inhibitors, relatively sharp resonances were observed for His86 and His88 and a broad resonance for His210, but the signal of His149 was too broad to be detected. Titration of BcII-Zn 2 with 5a resulted in a progressive decrease in the intensity of the imidazole NH signals of the free enzyme and a progressive increase in a new set of signals assigned to the enzyme-inhibitor complex (see ESI †). The intensity of the new peaks increased with the concentration of the inhibitor but their chemical shift was not affected. This behaviour is typical of a slow exchange between complexed and free enzyme, as observed for other compounds of the same class. 6 Analysis of the imidazole resonances for His88 and His210, which belong to different zinc binding sites, suggests that 5a binds predominantly in a single conformation, whereas 5b binds in two, or perhaps three, conformations (see ESI †).
The inhibitor titrations for 5a and 5b reveal that 5a binds more tightly to BcII than does 5b, an observation consistent with their respective K i values. The chemical shift changes, in the form of minimum chemical shift indices, 26 indicate that the binding of both compounds affects residues in the same loops near the active site (Fig. 4g, right panels) . Both 5a and 5b affect backbone amide resonances corresponding to the loops b6-a2 (84-88), b9-b10 (144-154), b11-a4 (168-188); in general, the minimum chemical shift difference index is somewhat greater for 5b, particularly for residues 83-91, 142-149 and 186-192. In terms of the chemical shift index, Asp90 and Arg91 are some of the BcII residues most affected by binding of 5a,b, as previously observed for mercaptocarboxylate inhibitors.
10
Compound 5a appears to make significantly more interactions with the "mobile" b3-b4 BCII loop, compared to 5b (Fig. 4g , left panel). Potent MBL inhibition has already been linked to the ability of an inhibitor to induce the b3-b4 loop closure.
8,9 5a but not 5b was observed to make a significant interaction with Val39 from the b3-b4 loop in solution, consistent with the modelling studies ( Fig. 4d ) and with our hypothesis for the design of 5a derivatives, i.e. the increase of the interactions with this conserved hydrophobic region.
Compound 5a apparently makes significant interactions with metal-coordinating histidines at both zinc coordination sites, and therefore its binding likely involves the previously observed bridging interaction between its thiolate and the two zincs. 5a also interacts significantly with the b3-b4 loop and the MBL conserved hydrophobic region, probably via its Ca methyl group.
Derivatives of 5a
We then sought to identify more potent inhibitors. Superimposition of the predicted L1-Zn 2 -5a complex with the IMP-1, BcII, CphA and FEZ-1 crystal structures revealed that (i) the methyl group of 5a could be positioned to make an interaction with the hydrophobic region conserved in all MBL active sites (Fig. 1) and (ii) derivatisation of 5a at the C-2 and/or C-3 positions (such as in compounds 6 and 7) would likely lead to structural clashes with the sub-class B2 CphA active site. These analyses prompted preparation of derivatives of 5a with bulkier hydrophobic groups at C-6; it was proposed that increasing the hydrophobicity at the C-6 position as well as restricting substitution at the C-2/C-3 positions would increase the potency vs. the B1 and B3 sub-classes and activity vs. the CphA MBL. Starting from the appropriate amino acids, 8a-c (Fig. 3) were synthesised in three steps from DL-phenylglycine, D-phenylalanine and D-valine, respectively (Scheme 1c).
Compounds 8a-c inhibited all the MBLs tested with K i values as low as 19 nM (Table 2) . CphA was also inhibited by 8a-c with K i values in the low micromolar range, i.e. these compounds are up to 20 times more potent at inhibiting CphA than 2. ESI-MS analyses (see ESI †) conducted with 8a-c and CphA also indicated the preferential formation of CphA-Zn-ligand complexes (and not CphA-Zn 2 -ligand such as observed with 1), supporting the importance of the monozinc-binding inhibition mode for potent inhibition of the CphA MBL by this thiol series (8a-c were up to 40 times more potent than 1 vs. CphA).
To investigate how 8a-c bind to MBLs, with both one and two active site zinc ions, further modelling analyses were then carried out. On this basis, all derivatives 8a-c were predicted (i) to interact with the zinc ions through chelation of the thiolate function (except for CphA), (ii) to have a near-superimposable backbone with the lead molecule 5a, (iii) to interact with the conserved hydrophobic region of the MBL active sites (Fig. 1) and (iv) to have a similar binding mode vs the dizinc enzymes BcII, IMP-1, L1 and FEZ-1 (Fig. 4h) . The docking of 8a-c with monozinc CphA resulted in high docking scores and suggested a near-identical binding mode to that of 5a to CphA, i.e. without a thiol-metal interaction, with an apparent increase in the hydrophobic interactions with the side chain of Val67 (Fig. 4i) .
Crystallographic analyses
To investigate the inhibition mechanism of 5a,b and derivatives 8a-c as well as to further test the modelling studies, we then cocrystallised 5a in complex with the sub-class B3 L1 MBL (Fig. 5a ). Analysis of the interactions between 5a and the L1 enzyme active site showed that the inhibitor thiolate bridges the two Zn(II) ions (S − -Zn1 = 2.3 Å ; S − -Zn2 = 2.4 Å ). The 5a inhibitor carboxylate group is positioned to form a hydrogen-bond with the Ser225 side chain (2.6 Å ). Hydrophobic contacts apparently occur between the inhibitor methyl group in C-6 and His263 (4.1 Å ) and Trp39 (4.2 Å ), and between C4-C7 and the side chains of His118 (3.7 Å ), Phe156 (4.1 Å ) and Pro227 (3.5 Å ). Furthermore, the crystal structure of L1-Zn 2 -5a is in agreement with and supports the docking studies (Fig. 5a) .
There is no reported X-ray diffraction study on the mode of binding of thiols to mono-zinc MBLs. To gain insight into the proposed binding mode of thiols such as 5a,b and 8a-c with the monozinc CphA MBL, where the modelling analyses suggested that the thiol does not chelate to the zinc, we attempted crystallisation of CphA-ligand complexes. We were able to obtain crystals of CphA-Zn in complex with 2, which diffracted to 1.7 Å resolution (Fig. 1c) . As revealed from the crystal structure of BlaBZn 2 -2 complex (Chryseobacterium meningosepticum), 27 2 acts as an inhibitor of sub-class B1 di-zinc MBLs with bridging of its thiolate group between the two active site metal ions (Fig. 5b) , as previously established for other thiolate inhibitors.
7,8 2 has also the ability to interact with monozinc enzymes via its thiolate group as reported with an Angiotensin Converting Enzyme (ACE)-Zn-2 crystal structure in which the thiolate function occupies the single tetrahedral coordination site left by the zinc-binding triad residues (Fig. 5d ).
28
In contrast to the crystal structures of the L1-Zn 2 -5a complex (Fig. 5a ) and the BlaB-Zn 2 -2 complex (Fig. 5b ) and in agreement with the modelling predictions (Fig. 4h) , the binding of 2 in the crystalline state was not by chelation to the zinc ion. Instead the main metal interactions between 2 and the monozinc CphA occur through the inhibitor carboxylate group, which coordinates a tetrahedrally cooordinated zinc ion (O2-Zn 2.1 Å ) (Fig. 5c) . The carboxylate O1 of 2 is positioned to hydrogen-bond with the side chains of His196 (3.1 Å ) and Asn233 (2.7 Å ). These residues approach the carboxylate group upon inhibitor binding via "closure" of the mobile loop, observed previously for the CphA enzyme. 5 The sulfhydryl group of 2 likely forms hydrophobic contacts with Phe156 (3.6 Å ) and the side chain of Arg233 (3.8 Å ) as well as with Trp87 (3.9 Å ), Leu161 (3.9 Å ) and Val67 (4.0 Å ). It is notable that, in contrast to the data for the Zn(II) complex reported here, evidence from EXAFS and PAC indicates that in the Cd(II)-substituted form of CphA, 2 appears to bind the zinc ion preferentially via its thiolate group.
11 Inhibitors such as Enalapril or Lisinopril (non-thiol analogues of 2) are reported to interact with the active site zinc ion of ACE via their carboxylate group, which occupies a similar position relative to the metal as the sulfhydryl group of 2 in complex with ACE-Zn. 29 It therefore seems likely that mercaptocarboxylate inhibitors of zinc hydrolases can interact with the zinc ion(s) of their target enzymes via either their carboxylate or their thiolate groups. It cannot be excluded that the mode of binding of 2 to CphA is influenced by the experimental conditions, i.e. higher pH values may favor sulfhydryl group ionisation, leading to better interaction with the metal ion.
To investigate the importance of the thiol group of 2 for inhibition of CphA and to test the results obtained by crystallographic studies, non-thiol derivatives of 2 were then synthesised (Fig. 3 , and Scheme 1 compounds 9 and 10) and tested for inhibition of CphA and IMP-1. Similarly, non-thiol derivatives of 8b were also synthesised ( Fig. 3 and Scheme 1 compounds 11 and 12) and screened under the same conditions. Compound 9 retained a significant level of inhibition of the CphA MBL (K i = 189 ± 12 lM), suggesting that the thiol group of 2 is not essential for the inhibition of CphA, in support of the crystallographic and modelling studies, indicating the thiol of 2 does not chelate to the zinc. In contrast, 9 was inactive (at 100 lM) against IMP-1, demonstrating that the replacement of the thiol group of 2 is detrimental to the inhibition of IMP-1, consistent with the apparently general mechanism of inhibition of the sub-classes B1 and B3 involving a thiol-zinc chelation. No inhibition was observed when 11 and 12 (at 100 lM) were tested against CphA and IMP-1, possibly reflecting the necessity of the thiolate group for potent inhibition of both monozinc and dizinc MBLs.
Conclusions
This work has demonstrated that it should be possible to develop individual compounds that are potent inhibitors of all three MBL sub-classes. An important structural point that has arisen is that the same compound may bind in different modes to different MBL sub-classes whilst still retaining inhibition activity. Specifically, crystallographic analyses revealed that whilst mercaptocarboxylate was observed to bind to the zinc ion via its thiolate group in the cases of the B1 and B3 sub-classes, for the B2 sub-class this binding mode was not observed. Instead, for the B2 CphA enzyme the thiolate group of 2 was observed to bind to the alcohol side chains of Thr119 and Thr157. In some cases, whether or not the thiol inhibitors preferentially bind with one or two zinc ions can be important to the potency of inhibitor observed. Thus, compounds that interact preferentially with monozinc CphA-Zn appear to be more potent than those that induce binding of a second zinc to give CphA-Zn 2 complexes (e.g. thiomandelate). The useful role of non-denaturing ESI-MS in rapidly providing data on metal binding stoichiometry, data that is often not easily obtained for metallo-proteins, is highlighted in this aspect of the work.
Overall, although the work reveals further complexities in the way that (thiol) inhibitors bind to different MBL sub-classes, it also suggests that utilisation of different binding modes for the same inhibitor binding to different MBL sub-classes may be a productive route to achieving potent broad-spectrum inhibition.
Experimental Crystallography
Crystallizations of the wildtype CphA and L1 were performed as described.
5, 16 The CphA-Zn-2 and L1-Zn-5a complexes were obtained by incubation (24 hours) of protein crystals in a drop of reservoir in which an excess of 2 or 5a was added. Before data collection, crystals were transferred to a cryoprotectant solution (reservoir solution containing 20% (v/v) glycerol), then mounted rapidly in loops and flash-cooled. X-Ray data for the CphA-2 and L1-5a complexes were collected at the beamline BM30A of the European Synchrotron Radiation Facility (Grenoble, France) and in-house using a Nonius View Article Online respectively. Data were processed using the CCP4 programs (Table  S1 †) . 30 Initial phases for the CphA-Zn-2 and L1-Zn-5a complex structures were generated by molecular replacement using the structure of the wildtype CphA and L1, respectively, as starting models (PDB accession code 1X8G and 1SML). Refinement was carried out using Coot 31 and REFMAC (CCP4). The calculation of the first (F o − F c ) electron density map clearly showed the presence of the inhibitor molecules in the active site. Inhibitors were modelled in the map after most of the protein main chain and side chain atoms and most of water molecules were built and refined. Conformational torsion-angle restraints and charges assignments for the 2 and 5a were obtained using CCP4i Libcheck.
Data collection and refinement statistics are shown in Table S1 †. Coordinates and structure factors have been deposited with the Protein Data Bank 32 with accession codes 2QDS and 2QDT.
NMR
Singly labelled ( 15 N) BcII protein used in all the NMR experiments was expressed and purified as described previously.
6 Sequencespecific resonance assignments for the BcII enzyme were obtained by using triple resonance experiments and will be published elsewhere. All NMR experiments were carried out in 20 mM MES, 100 mM NaCl, 0.2 mM ZnCl 2 , pH 6.4 at 298 K. Samples of the inhibitor-enzyme complexes were prepared by addition of microlitre volumes of inhibitor solutions (100-200 mM in MES buffer). 1D 1 H and 2D 1 H-15 N heteronuclear single quantum coherence (HSQC) spectra were used to establish when the complex was fully formed. The NMR spectra were obtained by using Bruker Avance DRX or DMX 600 MHz instruments.
1D
1 H spectra were obtained by using a water flip-back pulse combined with Watergate. 15 N HSQC (heteronuclear single quantum coherence) as previously described. 6 In the absence of resonance assignments for the inhibitor complexes, residues affected by inhibitor binding were identified by using minimum chemical shift approach. Here, the chemical shift difference between an amide cross-peak in the 1 H-15 N HSQC spectrum of the free protein (whose assignment is known) and the position of the nearest cross-peak in the corresponding spectrum of the enzyme-inhibitor complex is calculated. The 1 H and 15 N chemical shift differences, DH and DN, between each pair of cross-peaks provide the minimum chemical shift index based on the following formula:
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Whereas the true values of the chemical shift changes may be underestimated, the pattern of interactions observed by this approach has been found in a number of systems to be similar to the pattern seen when assignments are available for both free enzyme and the complex.
26,36
Kinetic analyses
Solution of 5a and 5b were prepared as 10 mM DMSO solutions before dilution with 20 mM HEPES buffer pH 7.0 containing 20 lg mL −1 BSA (and 100 lM ZnCl 2 where indicated). Tests verified that the low concentrations of DMSO present had no inhibition effects; the rate remained the same upon addition of 1% DMSO. The inhibitors 3, 4, 8a-c were prepared as 100 lM stock solutions directly into the buffer used. For these inhibitors the buffer was 20 mM PIPES buffer pH 6.0 containing 20 lg mL −1 BSA (and 100 lM ZnCl 2 where indicated). BcII, IMP-1, CphA, L1 and FEZ-1 enzymes were used at fixed concentrations between 0.03 and 0.7 nM. The enzyme and inhibitor were preincubated, when found to be necessary (see optimisation below), at room temperature before the substrate was added. Substrate concentrations were varied between 20 and 200 lM at a minimum of 2 inhibitor concentrations and in its absence. Hydrolysis of imipenem and nitrocefin was monitored by following the variation in absorbance at 300 nm or 482 nm respectively, using a Uvikon 860 spectrophotometer connected to a computer via a RS232 serial interface. Cells of 2 mm or 10 mm path length were used depending on substrate concentration. The experiments were performed at 30
• C and initial rate conditions were used to study the inhibition with imipenem or nitrocefin using the Hanes linearisation of the Henri-Michaelis equation and the KaleidaGraph 3.5 programme. Since the FEZ-1 MBL did not show competitive inhibition with these inhibitors, the IC 50 was determined at a substrate concentration of 200 lM nitrocefin.
To optimise preincubation times, an appropriate amount of enzyme was incubated with 100 lM inhibitor in a total volume of 5 mL in 10 mM HEPES buffer pH 7.0 (containing 100 lM ZnCl 2 with all enzymes except for CphA) at 30
• C. Samples of 490 lL were removed at various time intervals, 10 lL of 5 mM imipenem or nitrocefin was added and the activity measured at 30
• C.
Docking experiments
The program GOLD 37 (version 3.0) was used for docking analyzes. In GOLD, metal ions are considered to bind to hydrogen bond acceptors in the ligand. Coordination points are added at points around the metal, where coordination sites are missing. Tetrahedral and trigonal bipyramidal geometries were used for zinc metals in dizinc and monozinc MBLs respectively. These coordination points can then bind to acceptor atoms in the ligand. The ligands were prepared using MarvinSketch. 38 The proteins were prepared for docking using WHAT IF.
39 This online program generates proteins with the correct input for docking programs such as GOLD. All water molecules and ligands were removed from the proteins. For the dizinc MBLs the binding site of the ligands was defined as a 20 Å sphere centered at the zinc ion that is coordinated by the triad of zinc-binding histidine residues and default settings were applied. For CphA, the binding site was defined as a 20 Å sphere centered at the single zinc ion.
ESI-MS under mild ionisation conditions
Samples were desalted using a Microcon YM-10 (cut-off = 10 000 Da) centrifugal filters (Millipore, Bedford MA, USA) in 15 mM NH 4 Ac buffer (pH 7.5). Seven dilution/concentration steps were performed at 4
• C and 14 000 g. The stock enzyme solution was diluted in NH 4 OAc buffer to a final concentration of 100 lM. Prior to each experiment, individual thiols were freshly dissolved in DMSO at a final concentration of 100 mM. Each thiol was then diluted to 100 lM in 15 mM ammonium acetate buffer pH 7.5.
Samples were prepared by mixing the thiols and enzyme to a final concentration of 15 lM. An aliquot of this mixture was placed in a 96-well plate and analysed. ESI-MS analyses used a Q-TOF mass spectrometer (Q-TOFmicro Micromass, Altrincham, UK) interfaced with a NanoMate TM chip-based nano-ESI source (Advion Biosciences, Ithaca, NY, USA). Samples were infused to the Q-TOF through the ESI chip (estimated flow rate ca. 100 nL min −1 ). Typically a spraying voltage of 1.70 ± 0.1 kV depending on the "sprayability" of the sample and a sample pressure of 0.25 psi were applied. The instrument was equipped with a standard Z-spray source block. Clusters of Cs (n+1) I n (1 mg mL −1 CsI in 100% methanol) were used for calibration. Calibration and sample acquisitions were performed in the positive ion mode in the range of m/z 500-5000. Operating conditions for the mass spectrometer were: sample cone voltage 50 V, source temperature 40
• C. Acquisition and scan time were 30 s and 1 s, respectively. The pressure at the interface between the atmospheric source and the high vacuum region was fixed at 6.6 mbar (measured with the roughing pump Pirani gauge) by throttling the pumping line using an Edwards Speedivalve to provide collisional cooling.
Synthesis
General. All solvents used were either anhydrous solvents purchased from Aldrich (Sigma-Aldrich Chemical Co., Dorset, UK) or dried by passing over an alumina column under nitrogen pressure. Reagents were used as obtained from commercial sources unless otherwise stated. Measurement of pH was carried out using Prolabo Rota TM pH 1-10 paper. Flash chromatography was performed using silica gel (0.125-0.25 mm, 60-120 mesh) as the stationary phase. Thin layer chromatography (TLC) was performed on aluminium plates pre-coated with silica gel (Merck silica gel 60 F 254 ), which were visualized by the quenching of UV fluorescence (using an irradiation wavelength k = 254 nm), and/or by staining with iodine or 10% ammonium molybdate in 2 M sulfuric acid, followed by heating. Melting points were obtained using a Büchi 510 Cambridge Instruments Gallen III hot stage melting point apparatus. Infrared (IR) spectra were recorded as thin films between NaCl plates or as KBr discs on a Tensor 27 FT-IR Brüker spectrometer. Only selected absorbances are reported. Proton magnetic resonance spectra ( 1 H NMR) were recorded on a Bruker DPX 250 (250 MHz), Bruker DQX 400 (400 MHz), or Bruker AMX500 (500 MHz) spectrometers at ambient temperature.
1 H NMR spectral assignments are supported by 1 H-1 H COSY experiments where necessary. Coupling constant values (J) are reported to the nearest 0.5 Hz. Carbon magnetic resonance spectra ( 13 C NMR) were recorded on a Bruker DPX 250 (62.9 MHz), Bruker DQX 400 (100.6 MHz) or Bruker AMX500 (125.8 MHz) spectrometers at ambient temperature. 13 C NMR assignments were made using DEPT-135 along with HMQC, and HMBC correlation experiments. High-resolution mass spectra were recorded on a VG Autospec spectrometer by chemical ionization or on a Micromass LCT electrospray ionization mass spectrometer operating at a resolution of 5000 full width half height. High performance liquid chromatography (HPLC) used a Waters 996 photodiode array detector, a Waters 600E system controller and a Waters 717 plus autosampler, with a Phenomenex Synergy 4 l MAX RP80A (250 × 4.60 mm) column for analytical HPLC and a Phenomenex Luna 5 l C 18 (250 × 4.60 mm) column for preparative HPLC. 
Methyl 3,5-bis(bromomethyl)benzoate (14
1-Phenyl-2-sulfanylethanone (4)
. An aqueous solution of 1 N NaOH (8.25 mL, 8.25 mmol, 4 eq) was added to 17 (400 mg, 2.06 mmol, 1 eq) under a nitrogen atmosphere. The resulting mixture was stirred at 22
• C for 6 h. The reaction mixture was acidified with HCl (10 N) and extracted with EtOAc (2 × 20 mL). The combined organic extracts were washed with brine (2 × 20 mL), dried over MgSO 4 Methyl 2-(3-hydroxypropanamido)-3-phenylpropanoate (28) . To an ice-cooled suspension of D-phenylalanine methyl ester hydrochloride (1.00 g, 4.64 mmol) in absolute EtOH (10 mL) was added b-propiolactone (0.29 mL, 4.64 mmol) and sodium acetate (380 mg, 4.64 mmol). The resulting mixture was stirred at 22
• C for 15 h. The reaction mixture was partitioned between EtOAc (100 mL) and H 2 O (100 mL) and the aqueous phase was extracted with EtOAc (2 × 100 mL). The combined organic extracts were washed with brine (2 × 100 mL), dried over MgSO 4 
